Cardiac Amyloid Imaging
- ARSAC has noted a recent increase in enquiries for the use of 99mTc-HMDP for cardiac amyloid imaging.
- ARSAC is of the opinion that 99mTc-DPD is the preferred radiopharmaceutical for cardiac amyloid imaging. This position is consistent with advice from the National Amyloid Centre. However, the procedure code 99mTc-39-22 has now been updated to include 99mTc-HMDP.
- Employers or practitioners who wish to use 99mTc-HMDP for cardiac amyloid imaging and who have the procedure code 99mTc-39-22 on their licence (for diagnostic use) do not need to submit an amendment application to ARSAC to add 99mTc-HMDP to their licence.
- Any practitioner or employer who wishes to start a new service for cardiac amyloid imaging should submit an amendment application to ARSAC for the procedure code 99mTc-39-22. Full details of the training and the planned start up of the service should be included in the application.
- ARSAC advises that sites wishing to start a new cardiac amyloid service should liaise with the National Amyloidosis Centre for the best onward management of patients.
ARSAC Support Unit
Email: ARSAC@phe.gov.uk
Website: www.gov.uk/ARSAC
Telephone:
01235 825006